A 45-year-old man comes to the clinic for a routine follow-up visit. Four weeks ago, he wa… — USMLE Step 3

A $45$ -year-old man comes to the clinic for a routine follow-up visit. Four weeks ago, he was diagnosed with active pulmonary tuberculosis and started on a daily regimen of isoniazid, rifampin, pyrazinamide, and ethambutol, along with pyridoxine. He reports feeling much better, with resolution of his initial fever, night sweats, and cough. He specifically denies any abdominal pain, nausea, vomiting, dark urine, or unusual fatigue. He has no history of liver disease and does not consume alcohol. Vital signs are within normal limits. Physical examination shows no scleral icterus, and the abdomen is soft and non-tender with no hepatomegaly.

Laboratory studies show:

Test	Result	Reference Range
Total bilirubin	$0.9$ mg/dL	$0.1$ - $1.2$ mg/dL
Aspartate aminotransferase (AST)	$145$ U/L	$10$ - $40$ U/L
Alanine aminotransferase (ALT)	$160$ U/L	$10$ - $40$ U/L
Alkaline phosphatase	$95$ U/L	$40$ - $120$ U/L

Which of the following is the best next step in patient management?

Continue the current medication regimen and recheck liver function tests in 1 to 2 weeksAnswer
B
Discontinue isoniazid, rifampin, and pyrazinamide immediately
C
Obtain an ultrasound of the right upper quadrant of the abdomen
D
Schedule an outpatient ultrasound-guided liver biopsy
E
Admit the patient to the hospital for close clinical observation

Answer

Continue the current medication regimen and recheck liver function tests in 1 to 2 weeks.

The correct approach is to continue the current medication regimen and monitor closely. Isoniazid, rifampin, and pyrazinamide are all known to be hepatotoxic. Mild, asymptomatic elevation of aminotransferases is a common, often transient adverse effect observed during the first few weeks of therapy (occurring in

10\%

20\%

of patients). Standard guidelines recommend discontinuing hepatotoxic tuberculosis medications only if the aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels exceed

3

times the upper limit of normal (ULN) in the presence of symptoms (e.g., nausea, vomiting, abdominal pain, jaundice), OR if they exceed

5

times the ULN in the absence of symptoms. In this vignette, the patient's AST (

145

U/L) and ALT (

160

U/L) are approximately

4

times the ULN. Because he is completely asymptomatic, the threshold to discontinue therapy has not been reached.

Step-by-Step Solution

Evaluate the patient's symptoms related to potential hepatotoxicity.

The patient denies abdominal pain, nausea, vomiting, dark urine, or fatigue.

The presence or absence of symptoms determines the threshold for discontinuing hepatotoxic tuberculosis medications.

Analyze the laboratory results relative to the reference ranges.

AST is

145

U/L (roughly

3.6

times the upper limit of normal) and ALT is

160

U/L (

4

times the upper limit of normal). Total bilirubin and alkaline phosphatase are normal.

Quantifying the degree of aminotransferase elevation is required to apply standard treatment guidelines.

Apply standard management guidelines for drug-induced liver injury in tuberculosis treatment.

Since the patient is asymptomatic and the transaminases are less than

5

times the upper limit of normal, the regimen should be continued with close monitoring.

Mild asymptomatic transaminitis occurs in up to 20% of patients on isoniazid and often resolves spontaneously without requiring treatment interruption.

Key Concept

Management of first-line tuberculosis medication hepatotoxicity requires discontinuing drugs if aminotransferases exceed 3 times the upper limit of normal in symptomatic patients, or 5 times the upper limit in asymptomatic patients.

Estimated Time:1m 15s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic